Physician profile
Thomas R Conroy
NPI 1679539662
$8,561.90
in general payments reported to CMS, 2019-2025
24 companies · $2,344 in 2025
The $2,344 reported for 2025 was more than what 93% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.65 · 2021: $44.41 · 2022: $1,668 · 2023: $2,445 · 2024: $2,046 · 2025: $2,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,835.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,979.21 | 2022-2025 | Durysta, Vuity, Lumigan |
| Bausch & Lomb Americas INC. | $1,462.53 | 2022-2025 | Envista Mx60 Iol, Miebo, Infuse |
| Alcon Vision LLC | $903.90 | 2022-2025 | Total30, Dailies Total1, Precision7 |
| Dompe US, INC. | $778.17 | 2022-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $762.15 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $760.63 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $453.27 | 2022-2025 | Cequa |
| Oyster Point Pharma, INC. | $394.11 | 2022-2025 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $275.11 | 2022-2025 | Acthar |
| Astellas Pharma US INC | $122.83 | 2024 | Izervay |
| Lkc Technologies, INC. | $102.87 | 2024-2025 | |
| Thea Pharma INC. | $94.35 | 2023-2025 | Iyuzeh |
| Allergan, INC. | $74.35 | 2019-2022 | |
| Harrow Eye, LLC | $72.63 | 2024-2025 | Vevye |
| Coopervision INC. | $57.85 | 2023 | Misight Contact Lens, Myday Contact Lens |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $55.45 | 2022 | |
| Sight Sciences, INC. | $46.07 | 2022-2024 | Tearcare System |
| Glaukos Corporation | $40.25 | 2024-2025 | Idose, Idosetr |
| Amgen INC. | $32.08 | 2024 | Tepezza |
| Ani Pharmaceuticals, INC. | $32.06 | 2023 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $18.72 | 2023 | Syfovre |
| Eyevance Pharmaceuticals LLC | $15.00 | 2022 | |
| Tearlab Corp | $14.45 | 2023 | Tearlab Osmolarity System |
| Genentech USA, INC. | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Conroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.